The WT1 gene is expressed in 73–100% of patients with acute myelogenous leukemia
(AML) and is thought to play a role in maintaining the viability of leukemic cells. WT1 has …

We examined the presence of WT1-specific mRNA in bone marrow samples of 125 patients
with de novo acute myeloid leukemia at diagnosis by two-step RT-PCR. The sensitivity of the …

Introduction: WT1 overexpression is described in several oncological diseases including
acute myeloid leukemia (AML). Quantification of WT1 in bone marrow samples may be …

In order to verify if quantitative assessment of the WT1 transcript amount by the real time
quantitative PCR (RQ-PCR) can be used as a marker for minimal residual disease detection …

We have developed a sensitive, competitive, nested reverse transcription polymerase chain
reaction (RT‐PCR) titration assay that quantifies the number of Wilm's tumour (WT1) gene …

WT1 levels may be a useful predictor of leukemia free survival (LFS) following treatment of
acute myeloid leukemia (AML). We report a retrospective study in which levels of WT1 …

We studied the role of wt-1 as a minimal residual disease (MRD) marker in 46 patients with
acute leukemia (AL)(1st CR n= 24; 2nd CR n= 9, in relapse n= 13) after allogeneic bone …

The WT1 gene encoding a zinc finger polypeptide is a tumor suppressor gene that plays a
key role in the carcinogenesis of Wilms' tumor. Reverse transcriptase-polymerase chain …

In search for general PCR targets for minimal residual disease (MRD) studies in acute
myeloid leukemia (AML), Wilms' tumor gene 1 (WT1) expression was assessed by real-time …

WT1 overexpression is frequently identified in acute myeloid leukemia (AML) and has been
reported to be a potential marker for monitoring measurable residual disease (MRD). We …